The Bladder Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Bladder Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Bladder Cancer pipeline landscape and fostering the potential growth of Bladder Cancer therapeutic advancements.

 

Key Takeaways from the Bladder Cancer Pipeline Report

• DelveInsight’s Bladder Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
• The leading companies working in the Bladder Cancer market include CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co. Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
• Promising Bladder Cancer Pipeline Therapies in the various stages of development include Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, RC + PLND, Gemcitabine, Cisplatin, and others.
• In August 2023, Ferring Pharmaceuticals announced a study of Phase 3 Clinical Trials for ADSTILADRIN. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are “BCG Unresponsive” which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.
• In August 2023, Merck Sharp & Dohme LLC announced a study of Phase 3 Clinical Trials for Pembrolizumab and Enfortumab Vedotin. This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).

 

Request a sample and discover the recent advances in Bladder Cancer Treatment Drugs @ Bladder Cancer Pipeline Report

 

The Bladder Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Bladder Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Bladder Cancer clinical trial landscape.

 

Bladder Cancer Overview

Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men.

 

Find out more about Bladder Cancer Treatment Drugs @ Drugs for Bladder Cancer Treatment

 

Bladder Cancer Emerging Drugs Profile

• CG0070: CG Oncology
• N-803: ImmunityBio
• UGN-102: UroGen
• Trilaciclib: G1 Therapeutics

 

Bladder Cancer Pipeline Therapeutics Assessment

The Bladder Cancer pipeline report proffers an integral view of the Bladder Cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Bladder Cancer Pipeline Therapies @ Bladder Cancer Clinical Trials Assessment

 

Scope of the Bladder Cancer Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Bladder Cancer Companies- CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co. Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
• Bladder Cancer Pipeline Therapies- Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, RC + PLND, Gemcitabine, Cisplatin, and others.

 

Dive deep into rich insights for new drugs for Bladder Cancer Treatment, Visit @ Bladder Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Bladder cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Bladder cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CG0070: CG Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Trilaciclib: G1 Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MV-NIS: Vyriad
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. FEP 633: PRISM BioLab
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Bladder cancer Key Companies
21. Bladder cancer Key Products
22. Bladder cancer- Unmet Needs
23. Bladder cancer- Market Drivers and Barriers
24. Bladder cancer- Future Perspectives and Conclusion
25. Bladder cancer Analyst Views
26. Bladder cancer Key Companies
27. Appendix

 

For further information on the Bladder Cancer Pipeline therapeutics, reach out to Bladder Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting